Against the recommendation of its advisory committee on reproductive drugs, the Food & Drug Administration approved the use of a low-dose version of Paxil for hot flashes in menopausal women. The advisory committee had found that low-dose Paxil was not clinically more effective in reducing hot flashes than was a placebo, and voted against approval.
